简体中文
|
English
HOME
ABOUT US
Introduction
Company Culture
Management Team
RESEARCH CENTER
Product Pipelines
ADC Technology
NEWS AND MEDIA
CAREERS
CONTACT US
HOME
ABOUT US
RESEARCH CENTER
NEWS AND MEDIA
CAREERS
CONTACT US
NEWS AND MEDIA
Home
NEWS AND MEDIA
2019.07.11
First patient dosed with MRG001 in the phase I clinical study at Beijing Cancer Hospital
04/22
2019
Dr. Minmin Qin joins Shanghai Miracogen as SVP of CMC
04/10
2019
Synaffix Announces License Agreement Worth up to $125 Million with Leading Chinese ADC Developer, Shanghai Miracogen
02/21
2019
MRG001 IND approved by NMPA (formally known as CFDA)
11/27
2018
First patient dosed with MRG002 in the phase I clinical study at the Shanghai East Hospital of Tongji University
07/26
2018
MRG001 IND application formally accepted by CDE
FIRST
previous page
1
2
3
next page
END
